FT-002a
Pre-clinical- Indications
- Prostate cancer
Company intelligence / Profile preview
HBC Immunology
Alesund, Møre og Romsdal, NORWAYhofsethbiocare.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Developing peptide therapies targeting tumor microenvironments and immune cell regulation. Lead program FT-002a shows enhanced anti-tumor activity with enzalutamide in prostate cancer models[1][5]. MA-022a demonstrates reduced airway obstruction in asthma models[6].
- Therapeutic areas
- Oncology
- Modalities
- PeptidesOral formulations
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
(Academic collaborations implied but unspecified)
Beyond the preview
Go deeper on HBC Immunology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HBC Immunology.